MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying pressure. The excitement was due to the announcement on positive results of a clinical study testing symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes. Despite the fact that there has been a recent common shares financing scheduled, companies usually take their time and let the price consolidate before engaging in these activities, thus a short-term buy could be a smart investment. Towards the end of this alert a technical analysis will also be issued.

According to the ADA, the cost of diabetes care in the United States in

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in acute and critical care, recently announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes.

The purpose of the study was to test the performance of the company’s new, improved one-piece, cost-effective and easy-to-use biosensor. Echo Therapeutics’ non-invasive Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and is designed to provide diabetic patients with an affordable and easy-to-use, needle-free continuous glucose monitoring device. The study tested roughly 900 Symphony tCGM glucose readings paired with reference blood glucose measurements and the MARD for the study was 12.89 percent. There were no adverse events reported from the Prelude skin permeation or the Symphony tCGM biosensor.

Patrick Mooney, M.D., chairman and

Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009.

Echo’s pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with data from the “YSI Glucose Analyzer. The study will obtain about 900 data pairs for use in the analyses. The study will be blind to participating subjects and personnel working on the project and will include reference glucose measurements made at roughly 15 minute intervals for 24 hours.

Patrick T.